SKYE BIOSCIENCE INC(NASDAQ:SKYE) stock News

SKYE Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Chartmill - Mentions: LXEH FEMY ARBK SLDP ...

These stocks are moving in today's session

16 days ago - By: Chartmill - Mentions: XELB LXEH PALI ARBK ...

Let's take a look at the stocks that are in motion in today's session.

4 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

9 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

13 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

16 days ago - By: Benzinga - Mentions: AMD ONMD QUBT SPRB ...

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

16 days ago - By: Chartmill - Mentions: OMEX AMD LXEH FEMY ...

Monday's session: gap up and gap down stocks

16 days ago - By: Chartmill - Mentions: SANM AMD XELB ASNS ...

Wondering what's happening in today's pre-market session?

16 days ago - By: Skye Bioscience, Inc.

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

a month ago - By: Skye Bioscience, Inc.

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

2 months ago - By: Skye Bioscience, Inc.

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

2 months ago - By: Skye Bioscience, Inc.

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

2 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

2 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

3 months ago - By: The Motley Fool

Skye (SKYE) Q2 R&D Soars 249% No Revenue

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

3 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

4 months ago - By: Yahoo Finance - Mentions: HROW

William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating

4 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

4 months ago - By: Yahoo Finance - Mentions: PYPD

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

4 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

5 months ago - By: Zacks Investment Research - Mentions: NVO LLY CRBP

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

5 months ago - By: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming Investment Conferences

5 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

5 months ago - By: Skye Bioscience, Inc.

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

6 months ago - By: Skye Bioscience, Inc.

SKYE BIOSCIENCE INC (SKYE) Stock News

SKYE Latest News, Press Relases and Analysis

These stocks are moving in today's session

Let's take a look at the stocks that are in motion in today's session.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Monday's session: gap up and gap down stocks

Wondering what's happening in today's pre-market session?

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Earnings Scheduled For August 7, 2025

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association’s 85th Scientific Sessions

Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity